Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 24

From Innovation to Acquisition: CrossBridge Bio’s ADC Journey

Jul 29, 2026
As investment, innovation, and dealmaking continue to reshape the antibody-drug conjugate (ADC) landscape, Michael Torres, Chief Executive Officer of CrossBridge Bio, has shared his…
Read More...

COPD Foundations Joins the COPD Drug Development Summit

Jul 29, 2026
Are We Asking the Right Questions in COPD Drug Development? As the industry looks beyond traditional measures such as lung function and exacerbations, a new question is emerging: What…
Read More...

argenx to Acquire Forte Biosciences in $2.2 Billion Deal

Jul 29, 2026
argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion in cash, strengthening its immunology pipeline with a promising experimental therapy for autoimmune…
Read More...

BioMarin, n-Lorem Join Forces on ReNU Syndrome Therapy

Jul 29, 2026
BioMarin Pharmaceutical and the n-Lorem Foundation have entered a strategic collaboration to develop what could become the first disease-modifying treatment for ReNU syndrome, a rare…
Read More...

Pfizer, Eisai Partner to Co-Promote Nurtec in Japan

Jul 29, 2026
Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning…
Read More...

Biointron Launches RushData for AI-Powered Antibody Discover

Jul 27, 2026
Biointron Biological USA Inc. has introduced RushData, a new integrated service platform designed to accelerate antibody discovery by providing rapid experimental validation for…
Read More...

FDA Approves LYTENAVA for Wet Age-Related Macular Degeneration

Jul 27, 2026
Outlook Therapeutics has secured U.S. Food and Drug Administration (FDA) approval for LYTENAVA™ (bevacizumab-vikg), making it the first and only FDA-approved ophthalmic formulation of…
Read More...

Bora to Manufacture GERD Drug for U.S. Phase 3 Trial

Jul 24, 2026
Bora Pharmaceuticals and South Korea-based Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, an investigational…
Read More...

FDA Grants Fast Track Status to Lundbeck’s Narcolepsy Drug

Jul 24, 2026
Lundbeck has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Lu AH69593, its investigational oral orexin 2 receptor agonist being developed to treat…
Read More...

Affinia Gene Therapy Wins FDA Orphan Drug Status for Rare Heart Disease

Jul 24, 2026
Affinia Therapeutics has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its investigational gene therapy AFTX-201, marking another regulatory…
Read More...
Previous 1 … 22 23 24 25 26 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.